Families around the world will face imminent threat from antimicrobial resistant (AMR) super bugs without urgent and meaningful action towards a revolutionary new class of antimicrobials. The World Health Organization rates this problem as urgent and is one of the defining issues of our time.
Each year in the U.S., at least 2 million people get an antibiotic-resistant infection. Globally, billions of people are now infected with drug-resistant bacteria. These bacteria are now in the United States. Without access to next generation antibiotics that destroy bacteria's resistance to drugs, this pandemic will become a historic disaster.
Our peptoids have been shown by multiple independent labs to demonstrate broad-spectrum, extremely rapid antimicrobial killing kinetics against the 45 AMR bacteria tested-to-date, including drug resistant tuberculosis, drug resistant Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus (MRSA), any many other resistant ESKAPE bacteria.
Our peptoids' novel mode of action involves a flocculation and rigidification of internal cellular organelles, with minimal disruption of the cellular membrane mitigating horizontal transfer of microbial genetic information and appears to break the evolution of antimicrobial resistance.